Urothelial Carcinoma Training & Resources

Prescribing Information [External link]

KEYTRUDA® (pembrolizumab) + enfortumab vedotin▼ in unresectable or metastatic urothelial carcinoma (u/mUC)

KEYNOTE-A39/EV-302 Presentation

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.¹

Please refer to the Summary of Product Characteristics and risk minimisation materials before making prescribing decisions.

Reference

1. KEYTRUDA Summary of Product Characteristics.